Search results for " osteonecrosi"

showing 10 items of 103 documents

Kümmell's Disease: Clarifying the Mechanisms and Patients' Inclusion Criteria.

2014

The three major causes of vertebral body collapse include infection, malignant neoplasia, and trauma and it may be difficult to distinguish between them, particularly in the presence of severe osteoporosis. In 1891, however, Dr Hermann Kümmell, further added another possibility of vertebral body crush; the delayed posttraumatic collapse. As originally described, this rare clinical entity includes patients, who after a trivial trauma and an asymptomatic clinical course they develop a progressive vertebral body collapse and a painful kyphosis. Although more than a century has passed from its initial description, only few cases have been reported in the literature, whereas the main pathologic …

medicine.medical_specialtyPediatricsbusiness.industryKyphosisTime lagvertebral body collapseDiseasemedicine.diseaseAsymptomaticArticleSurgeryIntravertebral vacuum cleftresearch reviewKummell's diseasePathognomonicmedicineKümmell’s diseaseSevere osteoporosismedicine.symptomvertebral osteonecrosis.businessCollapse (medical)The open orthopaedics journal
researchProduct

Reply to Athanassios Kyrgidis, Zisis Teleioudis and Konstantinos Vahtsevanos’ Letter to the Editor re: Christian Walter, Bilal Al-Nawas, Knut A. Gröt…

2009

medicine.medical_specialtyProstate cancerBisphosphonate-associated osteonecrosis of the jawLetter to the editorbusiness.industryUrologyGeneral surgerymedicineAdvanced diseasebusinessmedicine.diseaseSurgeryEuropean Urology
researchProduct

A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis

2021

Abstract Denosumab is associated with the development of medication-related osteonecrosis of the jaw (MRONJ), an uncommon but severe oral side effect with a higher prevalence in metastatic cancer patients than in patients with metabolic bone fragility. Although several oral triggers can initiate MRONJ, invasive oral treatments and tooth extraction still remain the most common precipitating event. In general, tooth extraction and oral surgery should be avoided in patients at increased risk of MRONJ, while extraction of non-restorable teeth should be performed based on specific risk reduction protocols to eliminate dental/periodontal infections, still protecting from MRONJ onset. Based on th…

medicine.medical_specialtySide effectOsteoporosisSpecialties of internal medicine030209 endocrinology & metabolismMRONJOral surgery tooth extraction03 medical and health sciences0302 clinical medicineOral surgeryMedication-related osteonecrosis of the jawmedicineDenosumab osteoporosis; Medication-related osteonecrosis of the jaw; MRONJ; Oral surgery tooth extraction; Denosumab; Diphosphonates; Humans; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; OsteoporosisHumansIntensive care medicineGeneral Dentistrytooth extractionBisphosphonate-associated osteonecrosis of the jawDiphosphonatesBone Density Conservation Agentsbusiness.industryHypothesismedicine.diseaseosteoporosisDenosumab osteoporosisBone Density Conservation Agentsstomatognathic diseasesDenosumabOtorhinolaryngologyRC581-951030220 oncology & carcinogenesisDental surgeryOral and maxillofacial surgeryBisphosphonate-Associated Osteonecrosis of the JawNeurology (clinical)DenosumabbusinessOsteonecrosis of the jawmedicine.drugHead & Face Medicine
researchProduct

Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: A retrospective multi-hospital-based study of 87 Italian cases

2013

Abstract Background Bisphosphonates (BPs) are currently the chief drugs for the prevention/treatment of osteoporosis; one of their adverse effects is the osteonecrosis of the jaw (BRONJ). The primary endpoints of this multi-center cross-sectional study are: i) an observation of the clinical features of BRONJ in 87 osteoporotic, non-cancer patients; and ii) an evaluation of their demographic variables and comorbidities. Methods 87 BRONJ patients in therapy for osteoporosis with BPs from 8 participating clinical Italian centers were consecutively identified and studied. After BRONJ diagnosis and staging, comorbidities and data relating to local and drug-related risk factors for BRONJ were col…

medicine.medical_specialtyTime FactorsMultivariate analysisHeart DiseasesOsteoporosisSettore MED/50 - Scienze Tecniche Mediche ApplicateAdministration OralMandibleOsteonecrosis jawHospital based studyAdrenal Cortex HormonesRisk FactorsSettore MED/28 - Malattie OdontostomatologicheInternal medicineDiabetes MellitusInternal MedicinemedicineHumansIn patientRisk factorOral bisphopshonateAdverse effectOsteoporosis PostmenopausalAgedRetrospective StudiesAged 80 and overAlendronateBone Density Conservation AgentsDiphosphonatesbusiness.industryLiver DiseasesIncidence (epidemiology)Age FactorsMiddle Agedmedicine.diseaseSurgeryCross-Sectional StudiesItalyOral bisphopshonates; Osteonecrosis jaws; OsteoporosisHypertensionMultivariate AnalysisOsteoporosisBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawbusiness
researchProduct

Legal liability in bisphosphonate-related osteonecrosis of the jaw

2014

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is an adverse reaction that may occur in patients administered with bisphosphonates (BP). This condition can cause high morbidity and hinder quality of life. Its treatment is complex and often unsatisfactory, and prevention strategies may have limited effectiveness, if any. Thus, managing patients treated with BP may result in exposure of the practitioner to legal liability or malpractice claims: legal actions pursuant to BRONJ are reported to be underway on three continents. Nonetheless, the attribution of liability, if any, is a complex process requiring, on the basis of current knowledge, a robust and pragmatic approach to the facts…

medicine.medical_specialtybisphosphonate jawLegal liabilitybusiness.industrymedicine.medical_treatmentLiabilitySettore MED/50 - Scienze Tecniche Mediche ApplicateLiability LegalBisphosphonatemedicine.diseaseSurgeryQuality of life (healthcare)Settore MED/28 - Malattie OdontostomatologicheMalpracticemedicineHumansBisphosphonate-Associated Osteonecrosis of the JawCausationMedical prescriptionOsteonecrosis of the jawIntensive care medicinebusinessGeneral Dentistry
researchProduct

Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid : a systematic review and meta-ana…

2020

Background The aim of the present study was to analyse the incidence, risk ratio (RR) and prognoses of two types of medication-related osteonecrosis of the jaws (MRONJ): denosumab-related osteonecrosis of the jaws (DRONJ) and Bisphosphonate-Related Osteonecrosis of the Jaws (BRONJ) in cancer patients under treatment with denosumab or zoledronic acid (ZA). Material and Methods An electronic and manual search was conducted for randomized controlled trials (RCTs) until May 2019. Assessment of the identified studies, risk of bias and data extraction were performed independently by two reviewers. The incidence of DRONJ and BRONJ and the RR to develop MRONJ were calculated at 1 year, 2 years and …

medicine.medical_specialtymedication-related osteonecrosis of the jawsPHASE-3SKELETAL-RELATED EVENTSneoplasmsbisphosphonate-associated osteonecrosis of the JawsReviewBREASTZoledronic AcidDISEASElaw.invention03 medical and health scienceszoledronic acidDOUBLE-BLIND0302 clinical medicineRandomized controlled triallawInternal medicineNeoplasmsDentistry Oral Surgery & MedicinemedicineHumansGeneral DentistryRISKBONE METASTASESBisphosphonate-associated osteonecrosis of the jawScience & TechnologyOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesbusiness.industryIncidence (epidemiology)030206 dentistryOdds ratiomedicine.disease:CIENCIAS MÉDICAS [UNESCO]DenosumabZoledronic acidOtorhinolaryngologyMeta-analysisRelative riskUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawDenosumabbusinessLife Sciences & Biomedicinemedicine.drug
researchProduct

Oral Squamous Cell Carcinoma Mimicking Medication-Related Osteonecrosis of the Jaws (MRONJ): A Case Series

2021

(1) Background: Medication-related osteonecrosis of the jaw (MRONJ) is a potential adverse drug reaction of antiresorptive and/or antiangiogenic treatment. MRONJ is mostly diagnosed by anamnestic data, clinical examination and radiological findings, with signs and symptoms often unspecific. On the other hand, oral squamous cell carcinoma (OSCC) is characteristic for its pleomorphic appearance (e.g., ulcer, mucous dehiscence, non-healing post-extractive socket). We report three cases where OSCC mimicked MRONJ lesions. (2) Patients: Three patients undergoing amino-bisphosphonate treatment for osteoporosis presented with areas of intraorally exposed jawbone and unspecific radiological signs co…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryOsteoporosisONJPhysical examinationRK1-715Dehiscencemedicine.diseaseMRONJDermatologyOral Squamous Cell CarcinomaMedication-Related Osteonecrosis of the Jaws MRONJ Case Seriesoral squamous cell carcinomastomatognathic diseasesosteonecrosis of the jawRadiological weaponDentistrymedicinebone exposureIn patientBasal cellOSCCOsteonecrosis of the jawbusinessAdverse drug reaction
researchProduct

The use of pedicled buccal fat pad combined with sequestrectomy in bisphosphonate-related osteonecrosis of the maxilla

2010

The use of pedicled buccal fat pad flap (BFP) has proved of value for the closure of oroantral and oronasal communications and is a well-established tool in oral and maxillofacial surgery. Otherwise, the perceived limitations of surgical therapy for bisphosphonate-related osteonecrosis of the jaws (BRONJ) have been widely discussed, and recommendations have largely been made to offer aggressive surgery only to stage 3 patients refractary to conservative management. Oroantral communication may be a common complication after sequestrectomy and bone debridement in upper maxillary BRONJ. We report a case series of stage 3 recalcitrant maxillary BRONJ surgically treated with extensive sequestrec…

medicine.medical_specialtymedicine.medical_treatmentDentistryDehiscenceSurgical FlapsMaxillary DiseasesmedicineHumansOrthopedic ProceduresGeneral DentistryBuccal fat padMouthBisphosphonate-associated osteonecrosis of the jawDebridementbusiness.industryReview-ArticleMiddle AgedPlastic Surgery Procedures:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseMaxillary DiseasesSurgeryOtorhinolaryngologyAdipose TissueSequestrectomyMaxillaUNESCO::CIENCIAS MÉDICASOral and maxillofacial surgerySurgeryBisphosphonate-Associated Osteonecrosis of the JawFemaleOral Surgerybusiness
researchProduct

Analysis of different therapeutic protocols for osteonecrosis of the jaw associated with oral and intravenous bisphpsphonates

2017

Introduction Chemotherapy-associated osteonecrosis of the jaw caused by bisphosphonates is an exposure of necrotic bone with more than eight weeks of evolution that is attributable to bisphosphonates and no prior radiation therapy. Its etiopathogenesis remains unknown, although there are two hypotheses that may explain it: the drug’s mechanism of action, and the risk factors that can lead to osteonecrosis. There is a wide range of treatment options for managing chemotherapy-associated osteonecrosis of the jaw, from conservative treatments to surgical procedures of varying levels of invasiveness, which are sometimes supplemented with adjuvant therapies. Objectives The objective of this artic…

medicine.medical_specialtymedicine.medical_treatmentMEDLINEAdministration OralReviewIntravenous bisphosphonates03 medical and health sciences0302 clinical medicineClinical ProtocolsmedicineHumansStage (cooking)General DentistryPrior Radiation TherapyOral Medicine and PathologyDiphosphonatesbusiness.industry030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]SurgeryConservative treatmentOtorhinolaryngology030220 oncology & carcinogenesisRadiological weaponUNESCO::CIENCIAS MÉDICASAdministration IntravenousBisphosphonate-Associated Osteonecrosis of the JawSurgeryOsteonecrosis of the jawbusinessAdjuvant
researchProduct

Proposal for a preventive protocol for medication-related osteonecrosis of the jaw.

2021

Background Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse reaction experienced by some patients exposed to certain drugs (antiresorptives such as bisphosphonates or denosumab, and antiangiogenic drugs). From a review of the literature it appears that there is no uniform criterion when selecting preventive measures; these vary according to author. Likewise, the measures recommended are usually general, so that in few cases they result in specific actions to be applied depending on the different variables involved such as the type of drug used, the duration of its application, the underlying pathology, the presence or absence of risk factors, etc. The aim of this stud…

medicine.medical_specialtymedicine.medical_treatmentOsteoporosisMEDLINEReviewsleep disturbancesolder people03 medical and health sciences0302 clinical medicinemedicineHumansIntensive care medicineAdverse effectDental implantGeneral DentistryUNESCO:CIENCIAS MÉDICASProtocol (science)dental implantOral Medicine and PathologyedentulismBone Density Conservation AgentsDiphosphonatesbusiness.industryOsteonecrosis030206 dentistrymedicine.diseaseDenosumabSystematic reviewOtorhinolaryngologyOsteoporosisSurgeryBisphosphonate-Associated Osteonecrosis of the JawbusinessOsteonecrosis of the jawmedicine.drug
researchProduct